Key Takeaways
- The FDA advisory committee delivered a 7-2 vote favoring Grail’s Galleri multicancer test, concluding its benefits surpass potential risks.
- Safety received unanimous approval at 10-0, while effectiveness passed with a 6-4 decision.
- Shares of Grail surged 36% throughout the week, reaching approximately $108 per share.
- Canaccord Genuity maintained its Buy recommendation and increased the price target after the panel’s decision.
- Final regulatory clearance from the FDA may come in the upcoming months.
Grail (GRAL) shares are hovering around $108 following a positive recommendation from an FDA advisory committee regarding its Galleri multicancer blood screening technology. The stock experienced a 36% surge during the past week, with the majority of gains materializing in the two trading sessions preceding Wednesday’s panel meeting.
During Wednesday’s session, the Molecular and Clinical Genetics Devices Panel convened to evaluate Galleri’s regulatory pathway. Panel members delivered a 7-2 verdict, with one member abstaining, determining that the diagnostic tool’s advantages outweigh potential drawbacks.
Safety concerns were addressed with a perfect 10-0 vote. The effectiveness determination proved more contentious, passing with a 6-4 split.
Grail shares remained frozen throughout the entire trading day during the advisory meeting. The stock had already experienced significant appreciation following the release of encouraging briefing materials on Monday.
While the FDA retains ultimate authority and approval isn’t certain, the hearing’s trajectory suggests a favorable outcome. Market analysts anticipate a final determination within the coming months.
Understanding Galleri’s Technology
Galleri analyzes blood samples for DNA fragments bearing cancer cell markers. The technology identifies whether a cancer signal exists anywhere throughout the body, then provides an estimate of the signal’s tissue origin.
Clinical studies demonstrated Galleri’s capability to identify malignancies lacking conventional screening methods, such as ovarian and pancreatic cancers. While false positives occur infrequently, the test detects actual cancer approximately 50% of the time when malignancies are present.
This detection performance compares well with established diagnostic tools like mammography. Grail envisions patients utilizing existing single-cancer screening protocols in conjunction with Galleri, rather than as a replacement.
However, one clinical outcome introduces complexity. The NHS-Galleri trial conducted in the United Kingdom failed to demonstrate that screening reduced Stage IV cancer diagnoses one year post-testing.
Several panel members expressed concern that this data gap created uncertainty about Galleri’s life-saving potential. Notably, numerous currently widespread screening technologies, including colonoscopies, gained acceptance before long-term survival benefits were definitively established.
Revenue Projections and Wall Street Response
Grail currently markets Galleri at $950 per test, though insurance reimbursement remains limited. The company generated approximately $150 million in revenue last year, with current-year projections reaching $180 million.
Mizuho’s Bradley Bowers anticipates substantial revenue acceleration following regulatory approval. He referenced comparable cancer-screening products, including Cologuard and Guardant Health’s Shield test, which experienced sales doubling during their initial launch periods.
Legislative action has already occurred, with Congress enacting requirements for Medicare to evaluate coverage for tests like Galleri once FDA authorization is granted. UBS analyst Doug Schenkel projects Medicare reimbursement beginning in 2029 could contribute approximately $300 million to Grail’s revenue the subsequent year, driving total sales toward the $1 billion threshold.
Canaccord Genuity reaffirmed its Buy stance on Grail Wednesday, characterizing the hearing outcome as exceeding expectations. The firm interprets the panel’s benefit-risk assessment as a powerful indicator of ultimate approval.
Grail’s current market capitalization stands at $4.3 billion, representing roughly 19 times projected next-year revenue. This valuation reflects substantial approval probability already incorporated into the share price.
InvestingPro data indicates the stock is trading beyond the platform’s fair value calculation, with RSI metrics suggesting overbought territory following the recent rally. Profitability is not anticipated for the current fiscal year.
During its latest quarterly report, Grail disclosed revenue of $44.7 million, surpassing analyst consensus of $43.2 million, while posting a per-share loss of $2.56. Canaccord has scheduled a Friday webcast featuring two cancer screening specialists to analyze the panel’s conclusions and outline potential next steps.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
